-
公开(公告)号：US20240212366A1
公开(公告)日：2024-06-27
申请号：US18395084
申请日：2023-12-22
发明人： Shinji HANEDA
CPC分类号： G06V20/60 , G06V30/18 , G06V30/19013 , G06V30/19173 , G06V30/248
摘要： A drug identification apparatus determines which drug in the second-surface image of a package corresponds to a determined drug whose drug type has already been determined from the first-surface image which is an image of the other surface of the package, and present to a user, the determined drug and an undetermined drug in a second-surface image in such a manner that the determined drug and the undetermined drug may be differentiated from each other. Thus, the user may easily understand which drug needs the identification processing among the drugs in the second-surface image.
-
公开(公告)号：US11951092B2
公开(公告)日：2024-04-09
申请号：US16617739
申请日：2018-06-01
IPC分类号： A61K31/397 , A61K9/00 , A61P25/28
CPC分类号： A61K31/397 , A61K9/0053 , A61P25/28
摘要： An object of the present invention is to provide a drug which prevents progress of Alzheimer's disease and a method of preventing progress of Alzheimer's disease. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of suppressing brain atrophy and is useful as an agent for preventing or treating brain atrophy. Brain atrophy observed in aging or neurodegenerative diseases can be prevented or treated by administering 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
-
公开(公告)号：US11887293B2
公开(公告)日：2024-01-30
申请号：US17006414
申请日：2020-08-28
发明人： Koji Yokouchi , Kazuchika Iwami
CPC分类号： G06T7/0004 , A61J7/0076 , B65B57/14 , G06T7/97 , G06V10/141 , G16H20/13 , B65B9/087
摘要： A medicine verification device of the present invention includes: a detection unit that detects a boundary recess formed at a boundary position between a plurality of packaging bags each of which packs a medicine and is connected to form a continuous packaging bag having a strip-like shape; and an image capturing unit that captures an image of a surface of an imaging target portion on which at least the boundary recess is located a plurality of times while imaging conditions are changed in a state where light is emitted toward the surface of the imaging target portion in the continuous packaging bag, wherein the detection unit detects the boundary recess in the imaging target portion on the basis of the plurality of images captured while changing the imaging conditions by the image capturing unit.
-
公开(公告)号：US11707415B2
公开(公告)日：2023-07-25
申请号：US17512058
申请日：2021-10-27
发明人： Masanobu Takashima
CPC分类号： A61J7/0427 , A61J7/0481 , G16H20/10 , A61J2205/30
摘要： There is provided a medicine management system capable of checking a receipt status and a dosage stage of delivered medicines even at a delivery source. The medicine management system includes a management server for managing a receipt status and a dosage status of medicines to be delivered, a first terminal having a function of notifying the management server of information indicating receipt of medicines when the medicines have been received, a second terminal having a function of notifying the management server of information indicating dosage of medicines when the medicines have been taken, and a third terminal having a function of acquiring from the management server and displaying information on a receipt status and a dosage status of medicines.
-
公开(公告)号：US11548878B2
公开(公告)日：2023-01-10
申请号：US16760512
申请日：2018-10-30
发明人： Takeaki Yano , Kaori Miyamoto , Koichi Saito
IPC分类号： C07D409/12 , A61K31/397
摘要： Required are: a compound having high affinity for an emopamil binding protein; and a method for activating or inhibiting the emopamil binding protein, using such a compound. According to the present invention, provided is an emopamil binding protein binding agent comprising an alkyl ether derivative represented by the following formula [1] or a salt thereof: wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n, which are the same or different, each represent an integer of 1 to 6.
-
公开(公告)号：US11545254B2
公开(公告)日：2023-01-03
申请号：US16662233
申请日：2019-10-24
发明人： Kazuchika Iwami
摘要： An object of the present invention is to provide a dispensing audit support apparatus and a dispensing audit support method with a high collation accuracy robustness. According to a dispensing audit support apparatus according to one aspect of the present invention, since a position, shape and size of a region of interest are set according to a position of a collation-target medicine in a captured image, and a position, shape and size of a master image are set according to the set region of interest, it is possible to avoid or reduce distortion of the medicine shape, blur, inclusion of an end part into the image, and the like due to the position and orientation of the collation-target medicine. Therefore, influence on collation accuracy is small, and it is possible to enhance the robustness of the collation accuracy.
-
7.发明授权公开(公告)号：US11341357B2
公开(公告)日：2022-05-24
申请号：US16782943
申请日：2020-02-05
发明人： Kazuchika Iwami
IPC分类号： G06K9/62 , G06T7/586 , G16H70/40 , G06K7/14 , G06T5/00 , G06T7/00 , H04N5/225 , G06V10/145 , G06V10/75
摘要： A medicine inspection device, an image processing device, an image processing method, and a program are provided that appropriately extract identification information even when the positional relationship between a printed character and an engraved mark added to a medicine is not constant. The above problem is solved by an image processing device that performs a process of enhancing a printed character portion of a medicine based on at least one image taken with a surface of the medicine being irradiated with light to generate a printed-character-enhanced image, performs a process of extracting only an engraved mark portion from a three-dimensional shape of the medicine based on at least three images taken with illumination directions of the light to the surface of the medicine different from each other to generate an engraved-mark-extracted image, and generates a difference image between the printed-character-enhanced image and the engraved-mark-extracted image.
-
8.发明授权公开(公告)号：US11304928B2
公开(公告)日：2022-04-19
申请号：US16063833
申请日：2016-12-22
发明人： Atsushi Kano , Hiroyuki Inaba , Tai Oura
IPC分类号： A61K31/397 , A61K9/28 , A61K9/20 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/38 , A61P25/02
摘要： A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged storage, and exhibiting high impact resistance.
-
公开(公告)号：US20210312219A1
公开(公告)日：2021-10-07
申请号：US17349927
申请日：2021-06-17
发明人： Kazuchika IWAMI
摘要： A medicine identification system and a medicine identification method can favorable identification of a medicine using a camera-equipped mobile terminal. A smartphone including a camera changes a light-emitting region on a display, changes an illuminating direction with respect to a medicine placed on a tray having an indicator used for standardizing size and shape of the medicine, and images the medicine with different illuminating directions with the camera. The medicine identification device standardizes the size and shape of first images acquired by imaging based on the indicators captured in the first images, and extracts a medicine region image from each of the standardized first images. The medicine identification device then generates, based on the extracted medicine region images, a second image having undergone an emphasis process for emphasizing an embossed mark or a printed mark provided on the medicine, and identifies the medicine based on the generated second image.
-
公开(公告)号：US20200155505A1
公开(公告)日：2020-05-21
申请号：US16617552
申请日：2018-06-01
IPC分类号： A61K31/397 , A61P25/28
摘要： An object of the present invention is to provide a drug and a method which suppress progress of tauopathy such as Alzheimer's disease. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof has an effect of reducing the amount of phosphorylated tau protein and an effect of reducing the amount of amyloid β protein in the brain parenchyma, and thus is effective as an agent for preventing or treating tauopathy. Tauopathy can be prevented or treated by administering 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.035 秒)
